AbbVie could be heading for its second acquisition in the space of a month, with reports emerging of late-stage negotiations with Gilgamesh Pharmaceuticals, a central nervous system (CNS) drug ...

Less than a month after reports of takeover talks between AbbVie and Gilgamesh Pharma first emerged, the pair have gone public with details of a $1.2 billion deal – but it is not an acquisition. It ...

The history of Western and Near Eastern literature is anchored by two colossal figures who, though separated by over a millennium of history and the formidable geographical barriers between the Tigris ...

The Old Testament Torah speaks of the flood, which seems to have lasted for 40 days, in chapters 6, 7, and 8 of creation. Accordingly, God decides to destroy the evil that encompasses the world and ...

In 1853, Hormuzad Rassam discovered fragments of an ancient Sumerian text which is now considered to be the first great work of literature our civilization ever produced. After its translation it was ...

Until the Scientific Revolution most human cultures did not believe in progress. They thought the golden age was in the past, and that the world was stagnant, if not deteriorating. Strict adherence to ...

AbbVie’s (NYSE:ABBV) move to buy New York-based psychedelic drug developer Gilgamesh Pharmaceuticals in a deal worth around $1B, according to Bloomberg News, rallied the psychedelic space on Thursday.

AbbVie has reportedly added Gilgamesh Pharmaceuticals to its shopping list. The Big Pharma teamed up with Gilgamesh last year and, according to Bloomberg, is now in talks about buying the mental ...

The U.S. drugmaker has spent more than $20 billion on acquisitions since 2023 as sales of its top rheumatoid arthritis treatment, Humira, have slowed after losing patent protection. Gilgamesh is a ...

(Reuters) -Drugmaker AbbVie is in talks to acquire privately-held mental health therapeutics company Gilgamesh Pharmaceuticals in a deal worth about $1 billion, Bloomberg News reported on Wednesday, ...